Nabriva Therapeutics plc (NBRV):企業の財務・戦略的SWOT分析

◆英語タイトル:Nabriva Therapeutics plc (NBRV) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH137589FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company offers product candidate such as Xenleta (lefamulin), CONTEPO (fosfomycin), being developed in both intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia. Its other pipeline products comprise BC-7013 for the topical treatment of a variety of gram-positive infections including uncomplicated skin and skin structure infections; and Contepo to treat urinary tract infections. It partners with pharmaceutical and biotechnology companies. It has operational presence in Austria and the US. Nabriva is headquartered in Dublin, Ireland.

Nabriva Therapeutics Plc Key Recent Developments

Mar 11,2021: Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates
Mar 03,2021: Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021
Mar 01,2021: Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Feb 26,2021: Nabriva Therapeutics appoints Daniel Dolan as Chief Financial Officer

This comprehensive SWOT profile of Nabriva Therapeutics Plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Nabriva Therapeutics Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Nabriva Therapeutics plc – Key Information
Nabriva Therapeutics plc – Overview
Nabriva Therapeutics plc – Key Employees
Nabriva Therapeutics plc – Key Employee Biographies
Nabriva Therapeutics plc – Key Operational Heads
Nabriva Therapeutics plc – Major Products and Services
Nabriva Therapeutics plc – History
Nabriva Therapeutics plc – Company Statement
Nabriva Therapeutics plc – Locations And Subsidiaries
Nabriva Therapeutics plc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Nabriva Therapeutics plc – Business Description
Nabriva Therapeutics plc – Corporate Strategy
Nabriva Therapeutics plc – SWOT Analysis
SWOT Analysis – Overview
Nabriva Therapeutics plc – Strengths
Nabriva Therapeutics plc – Weaknesses
Nabriva Therapeutics plc – Opportunities
Nabriva Therapeutics plc – Threats
Nabriva Therapeutics plc – Key Competitors

Section 3 – Company Financial Performance Charts

Nabriva Therapeutics plc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Nabriva Therapeutics plc, Key Information
Nabriva Therapeutics plc, Key Ratios
Nabriva Therapeutics plc, Share Data
Nabriva Therapeutics plc, Major Products and Services
Nabriva Therapeutics plc, History
Nabriva Therapeutics plc, Key Employees
Nabriva Therapeutics plc, Key Employee Biographies
Nabriva Therapeutics plc, Key Operational Heads
Nabriva Therapeutics plc, Other Locations
Nabriva Therapeutics plc, Subsidiaries
Nabriva Therapeutics plc, Key Competitors
Nabriva Therapeutics plc, SWOT Analysis
Nabriva Therapeutics plc, Ratios based on current share price
Nabriva Therapeutics plc, Annual Ratios
Nabriva Therapeutics plc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Nabriva Therapeutics plc (NBRV):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bloomsbury Publishing Plc (BMY):企業の財務・戦略的SWOT分析
    Bloomsbury Publishing Plc (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Avivagen Inc (VIV):企業の財務・戦略的SWOT分析
    Summary Avivagen Inc (Avivagen), is a biotechnology company that provides drug development and animal healthcare products. It offers OxC-beta an active ingredient used to support the innate immune system and a healthy inflammatory condition of living beings. Avivagen's oxidized carotenoids promote a …
  • iPass Inc. (IPAS):企業の財務・戦略的SWOT分析
    iPass Inc. (IPAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Concord Medical Services Holdings Ltd (CCM):製薬・医療:M&Aディール及び事業提携情報
    Summary Concord Medical Services Holdings Ltd (CMS) is a diagnostic imaging center that offers clinical support services and laboratory services. The center offers radiotherapy and diagnostic imaging equipment services such as head gamma knife systems, body gamma knife systems and linear accelerator …
  • Koninklijke KPN NV (KPN):企業の財務・戦略的SWOT分析
    Koninklijke KPN NV (KPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Otonomy Inc (OTIC):製薬・医療:M&Aディール及び事業提携情報
    Summary Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company’s Otiprio is the US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients. Its pipeline portfolio encompasses Otividex for …
  • Bioanalytical Systems, Inc.:企業の戦略・SWOT・財務情報
    Bioanalytical Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bioanalytical Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Moberg Pharma AB (MOB):企業の財務・戦略的SWOT分析
    Summary Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged …
  • Hitachi Zosen Corporation (7004)-エネルギー分野:企業M&A・提携分析
    Summary Hitachi Zosen Corporation (Hitachi Zosen) is an industrial and engineering company that manufactures heavy industrial machinery. It conducts design and construction of process equipment, environmental systems, industrial plants, infrastructure-related equipment, disaster prevention systems, …
  • Alltech Inc:企業の戦略的SWOT分析
    Alltech Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Enzon Pharmaceuticals Inc (ENZN):製薬・医療:M&Aディール及び事業提携情報
    Summary Enzon Pharmaceuticals Inc (Enzon), formerly Enzon, Inc., is a pharmaceutical company that receives royalty revenues from existing licensing arrangements. The company has licensing arrangements with other companies related to sales of their four marketed drug products, namely, PegIntron, Syla …
  • Hewlett Packard Enterprise Co (HPE):企業の財務・戦略的SWOT分析
    Hewlett Packard Enterprise Co (HPE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • China Resources Beer (Holdings) Co Ltd:戦略・SWOT・企業財務分析
    China Resources Beer (Holdings) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China Resources Beer (Holdings) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Vertex Pharmaceuticals Inc (VRTX):企業の財務・戦略的SWOT分析
    Vertex Pharmaceuticals Inc (VRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Kuwait Gulf Oil Co:企業の戦略的SWOT分析
    Kuwait Gulf Oil Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Sinclair Pharma Ltd:企業の製品パイプライン分析
    Summary Sinclair Pharma Ltd (Sinclair), formerly Sinclair Pharma plc, is an aesthetics company, which provides dermatological solutions. The company develops, manufactures and distributes dermatological products for facial aesthetics, particularly for facial rejuvenation, through collagen stimulatio …
  • Global Bio-chem Technology Group Company Limited (809):企業の財務・戦略的SWOT分析
    Global Bio-chem Technology Group Company Limited (809) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • Shilpa Medicare Ltd (SHILPAMED):製薬・医療:M&Aディール及び事業提携情報
    Summary Shilpa Medicare Ltd (Shilpa Medicare) focuses on the development, manufacture and commercialization of generic pharmaceutical products and active pharmaceutical ingredients (APIs). It offers medicines for the treatment of cancer, infectious diseases such as HIV, multiple sclerosis and immuno …
  • Buy It Direct Ltd:企業の戦略的SWOT分析
    Buy It Direct Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Central Bank Of India
    Central Bank Of India - Strategy, SWOT and Corporate Finance Report Summary Central Bank Of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆